Core Viewpoint - Chip导科技's 2025 annual report reveals a mixed performance with revenue growth but a decline in net profit, while the company plans to expand into automotive electronics through strategic acquisitions [2][5]. Financial Performance - In 2025, Chip导科技 achieved revenue of 394 million yuan, an increase of 11.52% year-on-year [2]. - The net profit attributable to shareholders was 106 million yuan, a decrease of 4.91% compared to the previous year [2]. - The net profit after deducting non-recurring items was 68.89 million yuan, reflecting a growth of 17.54% year-on-year [2]. - The company plans to distribute a cash dividend of 4.30 yuan per 10 shares, totaling 50.57 million yuan, which accounts for 47.64% of the net profit [2]. Business Growth - Chip导科技's power semiconductor sales increased by 25.74% in 2025, driven by robust demand in the consumer electronics sector [3]. - The global semiconductor market is expected to continue its positive trend, with a projected revenue growth of 22.5% in 2025, reaching 772 billion dollars [3]. Research and Development - In 2025, Chip导科技 launched over 150 new power device products and holds a total of 141 valid intellectual property rights [4]. - The company emphasizes its commitment to technological innovation and value creation for customers [4]. Strategic Expansion - Chip导科技 plans to acquire 100% of Jishun Technology and 17.15% of Shunlei Technology, moving towards a Fab-lite model that includes design, packaging, and manufacturing [5]. - The total transaction value for these acquisitions is 403 million yuan, with performance commitments from Shunlei Technology for net profits in the coming years [5]. Industry Outlook - The overall performance of listed companies in the Shanghai market is showing a stable growth trend, particularly in the electronics, basic chemicals, and biopharmaceutical sectors [6]. - Companies like Lanke Technology and Dingtong Technology are also reporting significant profit increases, driven by trends in AI and communication technology [6].

2026 年 2 月 2 日 投资要点 ➢ 近期观点 1、医药指数本周关注 6 个子行业录得负收益。 2、中国生物医药产业正从"快速扩张"的 1.0 时代，迈入以"价值与 全球竞争力"为核心的 2.0 时代。其标志是：中国已成为全球第二 大新药首发市场，2025 年 1-8 月对外许可交易额突破 500 亿美元， 并在靶向蛋白质降解等颠覆性技术领域确立全球领导地位。支持 性的"全链条"政策与理性回归的资本市场，共同推动行业转向以 扎实临床数据、可持续商业模式和系统化能力为根基的高质量发 展阶段。这标志着中国正从全球创新的跟随者，转变为不可忽视 的引领力量。 团队成员 医疗与消费周报——价值深耕，全球突破：中国 生物医药创新观察（2026.1.26-2026.1.30） 1、市场状态高频数据库——1 月第 3 周—— 2026.01.26 2、地缘扰动、"抛售美债"与金银——2026.01.26 3、海外科技和商品是对美元债务的避险，中国定 价 资 产 有 望 成 为 长 期 主 线 — — 周 观 点 — — 2026.01.25 ➢ 风险提示 内卷风险；支付挑战；国际化短板 证 券 研 究 报 告 诚信专业 ...

Core Insights - The report emphasizes the continuous growth potential in the innovative pharmaceutical sector, particularly focusing on CXO, innovative drugs, and high-value consumables as key investment areas for 2025 [5][10][11] Performance Forecast - As of February 1, 2025, 261 pharmaceutical companies listed on A-shares have released performance forecasts, with 129 companies expected to be profitable. Among these, 85 companies anticipate profit growth, while 44 expect declines, and 25 are projected to turn losses into profits [6][7] - The report predicts the following profit growth rates for 28 pharmaceutical companies in 2025: - 2 companies with growth rates of 40% or more: SaiFen Technology and JiuZhou Pharmaceutical - 8 companies with growth rates between 20% and 40%: ZuoLi Pharmaceutical, AoRuiTe, HaoYuan Pharmaceutical, BiDe Pharmaceutical, DaSanLin, WoWu Biological, TeBao Biological, and HengRui Pharmaceutical - 10 companies with growth rates between 10% and 20%: BaiYunShan, LingRui Pharmaceutical, KaiLaiYing, PuRuiSi, YaoKang Biological, XiangSheng Medical, KeFu Medical, YiFeng Pharmacy, XinLiTai, and LanXiao Technology - 7 companies with growth rates between 0% and 10%: YunNan BaiYao, WeiEr Pharmaceutical, TongCe Medical, DongFuLong, JingXin Pharmaceutical, EnHua Pharmaceutical, and HuaDong Pharmaceutical - 1 company expected to turn losses into profits: BeiJi ShenZhou-U [7][8] Sector Analysis - The report highlights significant growth in the CXO, innovative drug, and high-value consumables sectors for 2025, driven by favorable conditions in the global innovative drug industry, increased order signing, and rising investment sentiment in both domestic and international pharmaceutical markets [10][11] - The high-value consumables sector benefits from the recovery of domestic surgical demand and improved profit margins following stabilized procurement prices. Some traditional Chinese medicine companies have also exceeded market expectations [10][11] - In contrast, sectors such as IVD, raw materials, vaccines, and blood products are facing performance pressures [10][11] Investment Recommendations - The report continues to recommend focusing on the innovative drug and CXO sectors, with specific companies highlighted for attention: - CXO sector: WuXi AppTec, Kanglong Chemical, KaiLaiYing, HaoYuan Pharmaceutical, BaiAoSaiTu, Tigermed, NuoSiGe, ZhaoYan Pharmaceutical, YiNuoSi, and PuRuiSi - Innovative drug sector: HengRui Pharmaceutical, BeiJi ShenZhou-U, NuoCheng JianHua, AiDi Pharmaceutical, and WeiXing Biological [5][10]

Core Insights - The article highlights three stocks that are expected to perform strongly in 2026, emphasizing their growth potential and market positioning. Group 1: Amazon - Amazon's share prices have lagged behind the S&P 500 over the past 12 months, but earnings growth is expected to drive future performance [2] - The company is focusing on improving efficiency, which is anticipated to continue positively impacting its bottom line [2] - Amazon Web Services (AWS) is expected to benefit significantly from the rise of agentic AI, with increased investments in AI leading to greater returns [3] Group 2: BeOne Medicines - BeOne Medicines has seen its stock price increase by over 50% in the last year, yet it remains underrated in the biotech sector [4] - The company's flagship product, Brukinsa, is recognized as the gold standard for treating various blood cancers, with sales expected to rise in both the U.S. and Europe [4] - BeOne has received regulatory approval in China for sonrotoclax and is awaiting U.S. approval, with potential for accelerated approval of another drug pending positive clinical results [6] Group 3: Enterprise Products Partners - Enterprise Products Partners offers a forward distribution yield of 6.6%, making it attractive for income investors [7] - The company has a strong track record of increasing its distribution for 27 consecutive years [7] - The anticipated boom in data center construction for AI applications is expected to drive demand for the company's natural gas pipelines, positioning it for growth [8]

1月31日，君实生物发布业绩预告，预计去年全年实现营业收入约25亿元，同比增长约28.32%；预计归母净利润亏损约8.73亿元，同比减亏31.85%；作为 创新药公司，公司自2020年7月上市以来至今已5年半，仍未扭转亏损态势，5年累计亏损约92亿元。 对于业绩变化，君实生物解释称，报告期内，主要系商业化药品的销售收入与上年同期相比有所增长。报告期内，公司核心产品特瑞普利单抗注射液(商 品名：拓益)于国内市场销售收入同比大幅增长。截至公告披露日，拓益已在中国内地获批上市的12项适应症全部纳入国家医保目录，是目录中唯一用于 肾癌、三阴性乳腺癌和黑色素瘤治疗的抗PD-1单抗药物。 公司表示，去年归母净利润仍出现亏损，但亏损金额相比显著缩窄，主要系公司商业化能力显著提升的同时不断加强费用管控与资源聚焦。 截至目前，特瑞普利单抗已在中国内地、中国香港、美国、欧盟、印度、英国、约旦、澳大利亚、新加坡、阿联酋、科威特、巴基斯坦、加拿大和巴林等 40多个国家和地区获批上市，并在全球多个国家和地区接受上市审评。 值得一提的是，最近几个月君实生物率遭股东减持。去年12月18日晚间，君实生物称，上海檀英计划通过大宗交易的方式减持 ...

Summary of Conference Call Notes Industry Overview - The focus has shifted back to company fundamentals in the China Pharma and Biotech sector, moving away from last year's emphasis on sector beta. [1] - Key companies discussed include BeOne, Kelun-Biotech, and Innovent, which have garnered significant investor attention. [1] BeOne - **Market Cap and Sales Potential**: BeOne's current market cap is $41 billion, with investors optimistic about Brukinsa's potential, expecting peak sales of $5 billion, which some consider conservative. [2] - **IRA Price Cut Exemption**: Brukinsa was not included in the recent IRA price cut announcement, leading to an expected sales upside of 10%-20%, potentially increasing peak sales to $6 billion by 2033. [2][6] - **Sonro Concerns**: Investors are worried about the lack of detailed data on Sonro's efficacy. However, the company believes these concerns are minor, as Sonro's trial results are comparable to venetoclax, which has a significant market presence. [2][9] Kelun Biotech - **Sales Expectations for sac-TMT**: Expectations for sac-TMT's sales range from $4-5 billion to over $10 billion, with Bernstein estimating $8 billion. [3] - **Phase 3 Data Catalyst**: The first global Phase 3 data release in 2026 is anticipated to be a major catalyst for stock performance. [3] - **Market Positioning**: Kelun's strategy focuses on squamous and PD-L1 high patients, avoiding direct competition with Dato-DXd, which targets non-squamous patients. [3][23] - **Market Size for 2L+ EGFRm**: The market for 2L+ EGFRm NSCLC is expected to be smaller than 1L TKIs, but projections indicate reasonable sales of CNY 4 billion. [3][25] Innovent - **Sales Focus**: Investors are primarily interested in mazdutide and IBI363, with concerns about pricing pressures due to competition from GLP-1 drugs. Sales estimates for mazdutide are expected to drop from CNY 3 billion to 2 billion in 2026. [4] - **Long-term Sales Estimates**: Despite short-term pressures, long-term estimates for mazdutide remain at CNY 5.4 billion and 10 billion at peak. [4] - **New Trials and Data**: Innovent is initiating six non-China Phase 1 trials in 2025, with expected readouts for new drugs, including IBI3003, which has received Fast Track designation from the FDA. [4] Financial Metrics - **Valuation and Performance**: The conference included a detailed ticker table with performance metrics for various companies, indicating significant upside potential for stocks like Kelun-Biotech and Innovent. [5] Additional Insights - **Regulatory and Competitive Landscape**: The discussions highlighted the importance of regulatory developments, such as the IRA price cuts, and competitive dynamics in the oncology market, particularly concerning CLL and AML treatments. [2][12][19] - **Clinical Trial Data**: The efficacy of treatments like Sonro and sac-TMT was compared against existing therapies, emphasizing the need for robust clinical data to support market positioning. [9][25] This summary encapsulates the key points from the conference call, focusing on the companies and industry dynamics discussed.

Core Insights - The biotechnology industry is rapidly developing and is a key direction for global technological revolution and industrial upgrading, with innovative drugs being a core engine aligned with the "Healthy China" strategy [1] - By 2026, the Hong Kong stock market's biotechnology sector is expected to see a significant increase in merger and acquisition activities, with Goldman Sachs predicting record-high global pharmaceutical and biotechnology M&A volumes [1] - The Chinese biotechnology sector is currently driven by a combination of policy benefits, capital support, and technological breakthroughs, with a shift in regulatory focus from cost control to encouraging quality innovation [1][2] Industry Trends - There is a persistent demand for the diagnosis and treatment of diseases such as cancer and cardiovascular conditions, supported by increased consumer payment capacity and rising healthcare expenditures, providing substantial growth opportunities for the industry [2] - The industry is transitioning from "broad innovation" to "differentiated innovation and international development," with a significant number of innovative drugs expected to be approved in China by 2025 [2] - In 2025, 76 innovative drugs are projected to be approved in China, with over 80% being domestic innovations, and a record total of over $130 billion in licensing transactions for innovative drugs [2] Investment Opportunities - The Hang Seng Biotechnology Index (HSBIO.HI) highlights the investment value of high-purity and scarce biotechnology companies, focusing on leading firms in the sector with a low overlap with traditional pharmaceuticals [3] - The index includes 30 leading biotechnology companies listed in Hong Kong, with a significant portion of its weight concentrated in the top ten stocks, including WuXi Biologics and BeiGene [3] - The Guangfa Hang Seng Biotechnology ETF, launched to facilitate efficient investment in core biotechnology assets, offers T+0 trading and low fees, positioning it as an attractive option for investors looking to capitalize on the sector's growth [3][4]

Investment Rating - The report suggests focusing on innovative drugs, brain-computer interfaces, and AI medical applications, indicating a positive outlook for these sectors [1]. Core Insights - The pharmaceutical industry index decreased by 3.31% this week, underperforming the CSI 300 index by 3.39 percentage points. However, since the beginning of 2026, the pharmaceutical sector has increased by 3.14%, outperforming the CSI 300 by 1.49 percentage points [5][12]. - The current valuation level (PE-TTM) for the pharmaceutical industry is 29.40 times, with a premium of 61.10% relative to the entire A-share market [22]. - Notable sub-sectors include blood products, which had the best performance this week with a decline of only 1.0%, while the top three performing sectors since the beginning of the year are hospitals (+12.0%), offline pharmacies (+9.3%), and medical R&D outsourcing (+6.7%) [28]. Summary by Sections Investment Strategy - The report highlights a robust combination of companies including 恒瑞医药 (Hengrui Medicine), 百济神州-U (BeiGene), 美好医疗 (Meihua Medical), and others, indicating their potential for growth and investment [19]. Market Performance - The pharmaceutical industry index's performance this week was ranked 23rd, while its year-to-date performance ranked 22nd among all sectors [5][20]. - The report notes that 60 stocks in the pharmaceutical sector had positive returns this week, while 420 stocks declined [35]. Company News - 先声药业 (Xiansheng Pharmaceutical) has authorized勃林格殷格翰 (Boehringer Ingelheim) for its drug SIM0709, with an upfront payment of €42 million and a total deal value of €1.058 billion [13]. - 石药集团 (Shijiazhuang Pharmaceutical) has partnered with 阿斯利康 (AstraZeneca) for a long-acting peptide project, which includes an upfront payment of $1.2 billion and potential milestone payments totaling $3.5 billion [14]. - 同源康 (Tongyuan Pharmaceutical) has its drug TY9591 included in the priority review list, expected to be launched in 2026, targeting EGFR mutation NSCLC brain metastasis patients [15]. Financial Data - The total market capitalization of the pharmaceutical industry is approximately ¥52,861.60 billion, with a circulating market value of ¥48,153.47 billion [3]. - The industry’s TTM PE ratio stands at 37.3, compared to the CSI 300's PE ratio of 14.2, indicating a significant premium for the pharmaceutical sector [3]. Additional Insights - The report emphasizes the importance of innovative drug development and strategic partnerships in driving growth within the pharmaceutical industry, particularly in the context of emerging therapies and technologies [1][19].

Investment Rating - The report maintains an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, while China National Pharmaceutical Group is rated "Neutral" [1]. Core Insights - The Hong Kong healthcare sector experienced a broad-based correction due to capital pressures, with pharmaceutical distribution remaining relatively stable [4][28]. - The Hang Seng Healthcare Index fell by 3.0% this week, underperforming the Hang Seng Index by 5.4 percentage points, but has gained 8.6% year-to-date, outperforming the Hang Seng Index by 1.7 percentage points [14][27]. - The top five gainers in the sector included Leads Biolabs-B (+19.3%), Sihuan Pharmaceutical (+17.9%), and Tigermed (+7.6%), while the bottom five decliners included Medlive Technology (-16.2%) and Laekna-B (-14.1%) [4][29]. Summary by Sections Market Performance - The report indicates that various sub-sectors within the healthcare market have experienced declines, with pharmaceutical distribution down by 0.3%, internet healthcare down by 2.1%, and medical devices down by 5.0% [4][28]. Company Updates - Rongchang Biopharmaceutical announced a revenue forecast of 3.25 billion yuan for 2025, representing a year-on-year increase of 89%, and has turned a profit [11]. - A collaboration agreement was signed between CSPC Pharmaceutical and AstraZeneca, involving a total payment of $18.5 billion for the licensing of GLP-1 long-acting assets [11]. - AstraZeneca plans to invest $15 billion in China by 2030, focusing on expanding drug manufacturing and R&D capabilities [12]. - Kangzheng Pharmaceutical's lebrikizumab cream has been approved for the treatment of non-segmental vitiligo in patients aged 12 and older [12]. Regulatory Developments - The National Health Commission approved a pilot program for internet-based first consultations in Beijing, which is expected to accelerate prescription outflow [13].

Group 1: Technology and AI - Alphabet (GOOGL US) is expected to maintain good visibility in its advertising business due to the gradual release of its valuation under pressure from AI search, with a projected cloud business growth rate of over 30% for the year [1] - Alibaba (BABA US) is anticipated to see a cloud business growth rate of 28%-30%, driven by strong demand in China, with significant contributions from its instant retail segment [1] - NVIDIA (NVDA US) is projected to achieve revenue exceeding 500 billion, with strong growth expected from its GB300 product line, which constitutes two-thirds of the Blackwell series [1] Group 2: E-commerce and Internet Services - Tencent (700 HK) is recommended as a top pick due to its strong investment in AI and steady growth in its core gaming and advertising businesses, with a target price of 700 [1] - Tencent Music (TME US) is expected to maintain a stable growth trajectory with a focus on subscription and non-subscription revenue streams, despite some margin pressure from new business initiatives [1] - Kuaishou (1024 HK) is projected to see significant revenue growth driven by its AI-enhanced content ecosystem, with a target price of 93 [2] Group 3: Healthcare and Pharmaceuticals - New Oxygen (SY US) is positioned well in the light medical beauty sector, with plans to expand its self-operated stores significantly by 2025, supported by a strong marketing capability and low customer acquisition costs [2] - Hansoh Pharmaceutical (3692 HK) is focusing on expanding its pipeline in oncology and other major indications, with a strong emphasis on innovative drug development [3] - BeiGene (6160 HK) is expected to exceed management's revenue guidance for 2025, driven by strong sales of its BTK inhibitor, with a projected peak sales potential of over 8 billion [4] Group 4: Energy and Materials - Saudi Aramco (ARAMCO AB) is positioned as a central player in global energy supply, with ongoing investments in hydrogen and carbon capture technologies, enhancing its long-term growth prospects [6] - MP Materials (MP US) is the only company in the U.S. with a fully scaled rare earth supply chain, benefiting from strong demand in the defense and renewable energy sectors [6] - Howmet Aerospace (HWM US) is expected to maintain a strong market position in gas turbine components, with a long order backlog supporting stable revenue growth [5]